BioLineRx (BLRX) Cash & Equivalents (2010 - 2025)

BioLineRx's Cash & Equivalents history runs 16 years deep, the most recent figure standing at $3.2 million for Q4 2025.

• On a quarterly basis, Cash & Equivalents fell 68.86% year-over-year to $3.2 million in Q4 2025; TTM through Dec 2025 was $3.2 million, a 68.86% decrease from a year earlier, with the FY2025 full-year figure at $3.2 million, down 68.86% from the prior year.
• Cash & Equivalents fell to $3.2 million in Q4 2025 per BLRX's latest filing, from $7.9 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $17.5 million in Q2 2021 and bottomed at $3.2 million in Q4 2025.
• The 5-year median for Cash & Equivalents is $9.9 million (2023), against an average of $10.2 million.
• Across the five-year window, Cash & Equivalents surged 216.57% in 2021 and plunged 68.86% in 2025, its largest moves.
• Year by year, Cash & Equivalents stood at $13.0 million in 2021, then dropped by 18.5% to $10.6 million in 2022, then plunged by 59.81% to $4.3 million in 2023, then soared by 145.26% to $10.4 million in 2024, then plunged by 68.86% to $3.2 million in 2025.
• Per Business Quant, the three latest BLRX Cash & Equivalents figures stand at $3.2 million (Q4 2025), $7.9 million (Q3 2025), and $7.2 million (Q2 2025).